The full content of Annals is available to subscribers

Subscribe/Learn More  >
Reviews |

Atrial Fibrillation: Restoration and Maintenance of Sinus Rhythm and Indications for Anticoagulation Therapy

Houtan Golzari, MD; Randall D. Cebul, MD; and Robert C. Bahler, MD
[+] Article, Author, and Disclosure Information

From Case Western Reserve University and MetroHealth Medical Center, Cleveland, Ohio. Acknowledgments: The authors thank Carol Smith for help with manuscript preparation, Dr. Louis Rakita for his helpful review, and the Brittingham Library Staff of MetroHealth Medical Center for their professional support. Requests for Reprints: Robert C. Bahler, MD, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH 44109-1998. Current Author Addresses: Dr. Golzari: 307-B Essex Street, Hackensack, NJ 07601.

Copyright ©2004 by the American College of Physicians

Ann Intern Med. 1996;125(4):311-323. doi:10.7326/0003-4819-125-4-199608150-00010
Text Size: A A A

Purpose: To review the efficacy and safety of electrical and pharmacologic conversion of atrial fibrillation, strategies for maintenance of sinus rhythm, and the importance of antithrombotic therapy.

Data Sources: English-language trials were identified from the MEDLINE database through 1995, bibliographic references, Current Contents, textbooks, and recent abstracts.

Study Selection: Randomized trials (including abstracts) were selected. Cohort studies were used if randomized trials were not available.

Data Extraction: Study design and data were extracted from clinical trials. Statistical analysis of combined data was not appropriate, given the marked variations in study designs and study populations.

Data Synthesis: Cardioversion restores sinus rhythm in more than 80% of patients. In atrial fibrillation of recent onset, pharmacologic regimens have a success rate of 40% to 90%. Sinus rhythm at 1 year is maintained in 30% of patients without antiarrhythmic therapy but in 50% of patients with such therapy. The efficacy and safety of antiarrhythmic drugs relative to one another are not established because trials done to date have been small and cases vary. Successful cardioversion and maintenance of sinus rhythm are most predictable when the duration of atrial fibrillation is brief.

Warfarin reduces the incidence of ischemic strokes and emboli in patients with nonvalvular atrial fibrillation from 4.5% to 1.4% per year. Aspirin (325 mg/d) appears to be equally effective in patients younger than 75 years of age who do not have hypertension or a history of thromboembolism or recent heart failure. Although warfarin is more effective than aspirin in preventing embolic strokes in patients older than 75 years of age, it may increase the incidence of hemorrhagic stroke and result in a similar rate of disabling stroke.

Conclusion: Cardioversion remains the preferred method with which to re-establish sinus rhythm. Long-term antiarrhythmic therapy is warranted only if recurrences or initial clinical instability are seen; pro-arrhythmic concerns and potential side effects should guide drug selection. Antithrombotic therapy is indicated for all patients older than 60 years of age and in all patients younger than 60 years of age who have clinical evidence of a primary cardiac disorder.


Grahic Jump Location
Figure 1. Atrial fibrillation of less than 48 hours' duration. Atrial fibrillation of more than 48 hours' duration. * = Consider transesophageal echocardiography; if no intracardiac thrombi are found, proceed directly to cardioversion while continuing anticoagulation therapy. The success rate of cardioversion exceeds that of pharmacologic conversion when the duration of atrial fibrillation is more than 2 or 3 days.
Algorithms for the management of atrial fibrillation applicable to patients other than those with recent stroke. Top.Bottom.
Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.